CN104768543A - 用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法 - Google Patents

用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法 Download PDF

Info

Publication number
CN104768543A
CN104768543A CN201280074486.2A CN201280074486A CN104768543A CN 104768543 A CN104768543 A CN 104768543A CN 201280074486 A CN201280074486 A CN 201280074486A CN 104768543 A CN104768543 A CN 104768543A
Authority
CN
China
Prior art keywords
methods
ugt
carcinoma
pterostibene
pterostilbene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280074486.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·巴托斯
瑞安·德林杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
University of California San Diego UCSD
Original Assignee
Chromadex Inc
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc, University of California San Diego UCSD filed Critical Chromadex Inc
Publication of CN104768543A publication Critical patent/CN104768543A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201280074486.2A 2012-05-08 2012-11-14 用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法 Pending CN104768543A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/466,827 US8841350B2 (en) 2011-05-11 2012-05-08 Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US13/466,827 2012-05-08
PCT/US2012/064993 WO2013169291A2 (en) 2012-05-08 2012-11-14 Method for inducing udp-glucuronosyltransferase activity using pterostilbene

Publications (1)

Publication Number Publication Date
CN104768543A true CN104768543A (zh) 2015-07-08

Family

ID=47142275

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280074486.2A Pending CN104768543A (zh) 2012-05-08 2012-11-14 用于使用蝶芪诱导udp-葡萄糖醛酸转移酶活性的方法

Country Status (12)

Country Link
US (2) US8841350B2 (enExample)
EP (1) EP2846785A4 (enExample)
JP (1) JP2015523963A (enExample)
KR (1) KR20150027081A (enExample)
CN (1) CN104768543A (enExample)
AU (1) AU2012379655B2 (enExample)
BR (1) BR112014027646A2 (enExample)
CA (1) CA2872623A1 (enExample)
IN (1) IN2014DN09990A (enExample)
MX (1) MX2014013503A (enExample)
WO (1) WO2013169291A2 (enExample)
ZA (1) ZA201408893B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160067193A1 (en) * 2014-09-04 2016-03-10 The Regents Of The University Of California Topical pterostilbene compositions for use in treating uv-induced skin damage and hyperplasia
EP3194032B1 (en) * 2014-09-04 2021-06-23 The Regents of the University of California Topical pterostilbene compositions for use in treating loss of barrier function in skin in burn injurys
WO2016200447A1 (en) * 2015-06-10 2016-12-15 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US12134956B2 (en) 2022-10-11 2024-11-05 Halliburton Energy Services, Inc. Liner hanger system
US12398624B2 (en) 2023-07-11 2025-08-26 Halliburton Energy Services, Inc. Self-energizing seal for expandable liner hanger

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175803A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for administering resveratrol and pterostilbene
WO2011042482A1 (en) * 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
WO2011097372A2 (en) * 2010-02-03 2011-08-11 Aptuit Laurus Private Limited Pterostilbene cocrystals

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6623724B2 (en) * 1996-09-18 2003-09-23 Applied Genetics Incorporated Dermatics Dermatological compositions and methods
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
DE10161253A1 (de) 2001-12-13 2003-06-26 Dragoco Gerberding Co Ag Verwendung von Dihydropinosylvin und dessen Derivaten als Inhibitoren
FR2869229B1 (fr) 2004-04-26 2006-08-25 Sederma Soc Par Actions Simpli Utilisation d'un inducteur des ugt par voie topique
ES2246165B1 (es) 2004-07-20 2006-12-01 Universitat De Valencia Uso combinado del pteroestilbeno y la quercetina para la fabricacion de medicamentos utiles en el tratamiento del cancer.
US8426369B2 (en) 2006-12-07 2013-04-23 Rutgers, The State University Of New Jersey Prevention and treatment of colon cancer
US8509879B2 (en) 2007-11-06 2013-08-13 The Regents Of The University Of California Apparatus and method for widefield functional imaging (WiFI) using integrated structured illumination and laser speckle imaging
US20090324740A1 (en) 2008-06-13 2009-12-31 Albritton Iv Ford D Novel nasal spray
US20100240767A1 (en) 2009-03-23 2010-09-23 Muhammed Majeed Melanogenesis inhibitiuon by 3,5-dimethoxy-4'-hydroxystilbenes and cosmeceutical compositions thereof
US9737495B2 (en) 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
US8883218B2 (en) * 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
WO2013051459A1 (ja) * 2011-10-02 2013-04-11 キユーピー 株式会社 ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175803A1 (en) * 2008-01-08 2009-07-09 David Rubin Method and compositions for administering resveratrol and pterostilbene
WO2011042482A1 (en) * 2009-10-06 2011-04-14 Green Molecular Polyphenols for use in the treatment of cancer
WO2011051483A1 (en) * 2009-10-30 2011-05-05 Green Molecular, S.L Pterostilbene (pter) for use in the prevention and/or treatment of skin diseases, damages or injures
WO2011097372A2 (en) * 2010-02-03 2011-08-11 Aptuit Laurus Private Limited Pterostilbene cocrystals

Also Published As

Publication number Publication date
EP2846785A4 (en) 2016-06-15
US20150011650A1 (en) 2015-01-08
WO2013169291A3 (en) 2015-06-18
AU2012379655A1 (en) 2014-11-20
KR20150027081A (ko) 2015-03-11
IN2014DN09990A (enExample) 2015-08-14
MX2014013503A (es) 2015-11-13
US20120289605A1 (en) 2012-11-15
WO2013169291A2 (en) 2013-11-14
AU2012379655B2 (en) 2018-01-18
US10039725B2 (en) 2018-08-07
ZA201408893B (en) 2016-08-31
US8841350B2 (en) 2014-09-23
EP2846785A2 (en) 2015-03-18
CA2872623A1 (en) 2013-11-14
JP2015523963A (ja) 2015-08-20
BR112014027646A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
Bowden Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling
Elshaer et al. Resveratrol: An overview of its anti-cancer mechanisms
Keum et al. Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-κB activation and tumor promotion
Gaidhu et al. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK
Luo et al. The role of COX-2 and Nrf2/ARE in anti-inflammation and antioxidative stress: Aging and anti-aging
Yajima et al. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor α and γ and reduce insulin resistance
US20140243267A1 (en) Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
Mody et al. The mechanisms of Fenretinide-mediated anti-cancer activity and prevention of obesity and type-2 diabetes
US10039725B2 (en) Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene
Chen et al. Selenoprotein P is elevated in individuals with obesity, but is not independently associated with insulin resistance
Chun-Bin et al. The main active components of Curcuma zedoaria reduces collagen deposition in human lung fibroblast via autophagy
Zhang et al. CoQ10 protects against acetaminophen-induced liver injury by enhancing mitophagy
Sampath et al. Activation of Nrf2 attenuates delayed gastric emptying in obesity induced diabetic (T2DM) female mice
CA3153879A1 (en) Curcuminoid composition for therapeutic management of metabolic syndrome
Chevillard et al. Nrf3-deficient mice are not protected against acute lung and adipose tissue damages induced by butylated hydroxytoluene
Takahashi et al. Apo-12′-lycopenal, a lycopene metabolite, promotes adipocyte differentiation via peroxisome proliferator-activated receptor γ activation
JP2007517836A (ja) 局所適用の脱色素組成物及び類似の組成物の調整でのイデベノンの使用
He et al. The effect of PPARγ ligands on UV‐or chemically‐induced carcinogenesis in mouse skin
Diaz et al. Differential effects of resveratrol on the dilator responses of femoral arteries, ex vivo
Yeh et al. Induction of phenolsulfotransferase expression by phenolic acids in human hepatoma HepG2 cells
Lluria-Prevatt et al. Skin cancer prevention
Romo-Robles et al. Effects of a Diet Supplemented with Fruit Antioxidants (Mango) on the Expression of Kir6. 2 (KCNJ11) in the Hippocampus and Kidney of Diabetic Rats
US12233032B2 (en) Compositions for management of polycystic ovary syndrome
PARKER et al. ook of A
Taïeb 5 Inhibitors and Enhancers of Melanogenesis Alain Taïeb, Muriel Cario-André, Stefania Briganti, and Mauro Picardo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150708

WD01 Invention patent application deemed withdrawn after publication